Skip to content

Intratympanic steroid injection versus systemic steroid for improving hearing in idiopathic sudden sensorineural hearing loss patients

Intratympanic steroid injection versus systemic steroid for improving hearing in idiopathic sudden sensorineural hearing loss patients

Status
Unknown
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20211018002
Enrollment
60
Registered
2021-10-18
Start date
2021-11-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Methods to improve hearing from idiopathic sudden sensorineural hearing loss Intratympanic steroid, sudden sensorineural hearing loss

Interventions

Methylprednisolone 0.4-0.8 ml will be injected at posteroinferior quadrant of tympanic membrane of affected ear weekly for 2 weeks,Prednisolone 1 mg/kg/day is given to the patient continually 7 days
Active Comparator Drug,Active Comparator Drug,Active Comparator Drug,No Intervention Drug
Intratympanic Methylprednisolone,Oral prednisolone,Intratympanic methylprednisolone and oral prednisolone,no intervention

Sponsors

None listed

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Patients who have been diagnosed sudden sensorineural hearing loss by losing pure tone average within 40-70 decibels for at least 3 consecutive frequencies 2.Onset starts within 7 days prior to hospital 4.Must be idiopathic cause 5.Never been treated this condition before 6.Unilateral side 7.can speak Thai

Exclusion criteria

Exclusion criteria: 1. active conditions of external/middle ear disease 2.History of surgery/trauma at head and neck area prior onset of symptom 1 month 3.congenital hearing loss 4.Poor controlled of underlying disease eg. poor controlled DMT2,ESRD 5.History of Meniere disease 6.History of radiotherapy/chemotherapy/ototoxic drugs usage prior onset of symptom 2 weeks 7.underlying retrocochlear pathology 8.active pulmonary tuberculosis/parasitic infestation 9.severe osteoporosis, congestive heart failure, Cushing's syndrome, psychiatric disorders, glaucoma

Design outcomes

Primary

MeasureTime frame
level of hearing improvement 2 weeks,4weeks,2months,3months Pure tone audiogram

Secondary

MeasureTime frame
improvement of otological symptoms 2 weeks, 4weeks, 2 months, 3 months Visual analog score

Countries

Thailand

Contacts

Public ContactRawisara Sritrakool

Otorhinolaryngology department

rawisr@kku.ac.th0842702444

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026